Pharmaceutical Market Europe • March 2026 • 3
COMMENT
In our cover story this month, Danny Buckland looks at pushing communications to new heights, with the advance of AI in the digital age, and why staying connected through core messaging remains critical, even as new comms excellence opportunities abound.
As Danny says: “Research shows that 65% of senior clinicians in the UK, Europe and the US have stopped engaging with pharma companies because of poor digital delivery, with The Value Gap research by Graphite report concluding that ‘the path forward is not more digital – it is more meaningful digital’. Read more on page 28
In this issue we also have an article from Karen Westaway: Hidden figures – the implementation gap in medicines access laid bare, that highlights how new data is lifting the lid on how nationally recommended medicines stall in local systems.
As Karen says: “In pharma market access, the gap between national endorsement and local implementation is a recurring feature of healthcare systems across Europe. Therapies judged clinically effective and cost-effective at a national level are routinely taking months longer to reach the patients they were intended to help. The net result: people are waiting longer than necessary for access to breakthrough treatments.” Read more on page 18.
Another highlight of this issue is an article by Jacqueline Barry: Unlocking the UK’s advanced therapy pipeline, looking at how the UK’s challenge does not lie in innovation, but in ensuring new therapies can progress through the full development and clinical trial pathway.
And rounding off the issue, we have an article on women’s health from Karolina Afors: Closing the hormonal gap. By 2030, nearly 500 million women worldwide will be experiencing menopause, equalling around 6% of the global population – this article talks about why testosterone deserves greater focus in women’s health.
Our May issue will look at improving market access through overcoming regulatory hurdles, negotiating pricing and engaging with stakeholders. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Journalist/Editorial Assistant
Lucy Batizovszky
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2026 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW